Search results
Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark
Zacks via Yahoo Finance· 2 weeks agoAbbott ABT recently received a CE Mark in Europe for the AVEIR dual chamber (DR) leadless pacemaker...
Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker
Zacks via Yahoo Finance· 12 months agoAbbott ABT recently received FDA approval for its pioneering AVEIR dual chamber (DR) leadless...
Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
Zacks via Yahoo Finance· 1 year agoAbbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled...
Abbott’s dual chamber pacemaker receives CE Mark
Medical Device Network via Yahoo Finance· 2 weeks agoAbbott has obtained a CE Mark in Europe for its AVEIR dual chamber (DR) leadless pacemaker system, marking a significant advancement in cardiac rhythm...
Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result
Zacks via Yahoo Finance· 1 year agoAbbott Laboratories, Inc. ABT presented new data from an investigator-sponsored European study —...
Abbott's (ABT) New Positive Data Favors OCT in Stent Implantation
Zacks via Yahoo Finance· 10 months agoAbbott Laboratories ABT recently announced late-breaking data from the first-of-its-kind ILUMIEN IV...
Abbott (ABT) Q3 Earnings and Revenues Surpass, Margins Dip
Zacks via Yahoo Finance· 8 months agoAbbott Laboratories ABT reported third-quarter 2023 adjusted earnings of $1.14 per share, which...
Abbott Laboratories (ABT) Q3 2023 Earnings: Strong Performance Despite COVID-19 Testing Sales ...
GuruFocus.com via Yahoo Finance· 8 months agoAbbott Laboratories (NYSE:ABT) reports Q3 2023 sales of $10.1 billion, a decrease of 2.6% due to...
Down 10.3%, Is Abbott Laboratories Stock a Buy on the Dip?
Motley Fool· 10 months agoIf you're trying to build a passive income stream to eventually fuel your dream retirement, Abbott...
Abbott's (ABT) MitraClip Device Shows Favorable Outcome
Zacks via Yahoo Finance· 1 year agoAbbott Laboratories, Inc. ABT recently presented late-breaking data from the Landmark COAPT trial...